Abstract：Objective: To investigate the role of alendronate anti-osteoporosis in fracture healing and prevention of re-fracture after vertebroplasty for osteoporotic vertebral compression fracture (OVCF). Methods: A total of 99 patients with OVCF who underwent PVP in our hospital from August 2021 to August 2022 were selected and randomly divided into control group (49 cases) and study group (50 cases). The control group was given basic anti-osteoporosis intervention after surgery, and the study group was given new generation bisphosphonate on the basis of the control group after surgery. The treatment continued 6 months. Postoperative rehabilitation, pain level (VAS score), lumbar spine function (ODI score, JOA score), bone mineral density, bone turnover indexes [N-terminal mid-portion osteocalcin (N-MID-OT), β-collagen special sequence (β-CTX), and total type 1 collagen amino-terminal prolongation peptide (T-P1NP)], vertebral stability indexes (height ratio of the injured vertebrae, Cobb's angle of the injured vertebrae), and incidence of re-fracture were compared in the two groups were compared. Results: The fracture healing time and recovery time of the study group were shorter than those of the control group (P<0.05). After 3 and 6 months of treatment, VAS, ODI scores and Cobb Angle of injured vertebra in the study group were lower than those in the control group, while JOA scores, height ratio of injured vertebra, Ward triangle and bone density of femoral neck in the study group were higher than those in the control group (P<0.05). The serum levels of N-MID-OT, β-CTX and T-P1NP in the study group were lower than those in the control group after 1 month, 3 months and 6 months of treatment (P<0.05). The incidence of refracture in the study group was lower than that in the control group (P<0.05). Conclusion: Alendronate combined with PVP in the treatment of OVCF improves bone metabolism, promotes fracture healing, reduces the incidence of postoperative re-fracture, and has significant advantages in the recovery of patients' lumbar spine function and pain relief.
廖丹, 钱黎. 阿仑膦酸钠在骨质疏松椎体压缩性骨折椎体成形术后应用价值[J]. 河北医学, 2023, 29(12): 1998-2004.
LIAO Dan, QIAN Li. The Value of Alendronate after OVCF Vertebroplasty. HeBei Med, 2023, 29(12): 1998-2004.
[1] American college of obstetricians and gynecologists' committee on clinical practice guidelines-gynecology.Osteoporosis prevention,screening,and diagnosis:ACOG clinical practice guideline No.1[J].Obstet Gynecol,2021,138(3):494-506. [2] Kutsal FY,Ergin Ergani GO.Vertebral compression fractures:still an unpredictable aspect of osteoporosis[J].Turk Med Sci,2021,51(2):393-399. [3] Kobayashi N,Noguchi T,Kobayashi D,et al.Safety and efficacy of percutaneous vertebroplasty for osteoporotic vertebral compression fractures:a multicenter retrospective study in Japan[J].Interv Radiol (Higashimatsuyama),2021,6(2):21-28. [4] Dai C,Liang G,Zhang Y,et al.Risk factors of vertebral re-fracture after PVP or PKP for osteoporotic vertebral compression fractures,especially in Eastern Asia:a systematic review and meta-analysis[J].Orthop Surg Res,2022,17(1):161. [5] Basso FG,Pansani TN,Cardoso LM,et al.Influence of bisphosphonates on the behavior of osteoblasts seeded onto titanium discs[J].Braz Dent,2020,31(3):304-309. [6] Lu A,Wang X,Huang D,et al.Percutaneous curved vertebroplasty for osteoporotic vertebral compression fracture[J].Asian Surg,2022,45(10):2050-2051. [7] Mao W,Dong F,Huang G,et al.Risk factors for secondary fractures to percutaneous vertebroplasty for osteoporotic vertebral compression fractures:a systematic review[J].Orthop Surg Res,2021,16(1):644. [8] 陈孝江,郭友忠.老年骨质疏松性脊柱骨折患者应用阿仑膦酸钠联合经皮穿刺椎体成形术治疗效果分析[J].山西医药杂志,2020,48(11):1379-1382. [9] Black DM,Geiger EJ,Eastell R,et al.Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates[J].N Engl Med,2020,383(8):743-753. [10] Biernat M,Szwed-Georgiou A,Rudnicka K,et al.Dual modification of porous Ca-P/PLA composites with APTES and alendronate improves their mechanical strength and cytobiocompatibility towards human osteoblasts[J].Int Mol Sci,2022,23(22):14315. [11] Yu F,Xia W.The epidemiology of osteoporosis,associated fragility fractures,and management gap in China[J].Arch Osteoporos,2019,14(1):32. [12] 尉志强,赵东方,关丽萍,等.经皮椎体成形术联合阿仑膦酸钠治疗对骨质疏松性脊柱骨折患者血清B-ALP、N-MID-OT、T-P1NP及β-CTX水平的影响[J].国际检验医学杂志,2019,40(7):835-838. [13] Cavalier E,Lukas P,Bottani M,et al.European biological variation study (EuBIVAS):within- and between-subject biological variation estimates of β-isomerized C-terminal telopeptide of type I collagen (β-CTX),N-terminal propeptide of type I collagen (PINP),osteocalcin,intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein-a cooperation between the EFLM working group on biological variation and the international osteoporosis foundation-International federation of clinical chemistry committee on bone metabolism[J].Osteoporos Int,2020,31(8):1461-1470. [14] 邓强,乔小万,李中锋,等.骨质疏松性椎体压缩骨折椎体成形术后非手术椎体再骨折危险因素探讨[J].中国骨质疏松杂志,2021,27(4):613-617,624. [15] Yang D,Tan J,Long Y,et al.Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis:a prospective study[J].Aging Clin Exp Res,2023,35(3):531-539.
2023, Vol. 29 
冀公网安备13080202000677号